Abstract (EN):
Drug discovery is inherently a multi-objective problem in which the modeling of decision preferences and constraints and
the visualization and assessment of the trade-offs among objectives is yet a great challenge. As the desirability theory is a well-known multicriteria decision-making approach, it has been decided to apply it, instead for multi-objective optimization
[1], to the rational design and development of adenosine agonist ligands, specifically as a prediction model tool to extract
useful information on the desired trade-offs between binding and relative efficacy of A3 adenosine receptor agonists
(N6-substituted-4′-thioadenosine type). The development of a linear prediction model of the A3 agonists overall desirability,
as well as the desirability analysis of this model, leads to discover significant clues based on simple molecular descriptors
with a direct physicochemical or structural explanation. The information retrieved guides to the design of new candidates
with simultaneously improved binding and relative efficacy profiles. In particular, the model suggests a relevant role of the
presence of cyclic substituents on the N6 position of the adenine ring that in turn contributes to reduce the flexibility and
hydrophobicity of the molecules. Although based on a simple 1D model, the data obtained correlate well with the results
previously reported with more sophisticated approaches such as 3D-COMFA [2]. In addition, the model offers other
benefits: the simultaneous analysis of both binding and relative efficacy profiles of A3 agonists as well as the design of
highly potent and selective agonists based on a particular and unusual structural modification. In summary, it was
demonstrated that desirability theory could be a valuable tool in medicinal chemistry, namely in the development of novel
and potent A3 agonist candidates.
Language:
English
Type (Professor's evaluation):
Scientific
Contact:
fborges@ff.up.pt
Notes:
in Third joint Italian-German Purine Club meeting: “Purinergic receptors: new frontiers for novel therapies”